Syneron Medical Ltd. (NASDAQ: ELOS) announced
that it has entered into an agreement with
Fluorinex Active, an Israeli-based start-up to
develop advanced fluoridation and tooth whitening
devices for dentists and consumers.
Fluorinex has developed a unique device that
delivers fluoride ions directly to the tooth
enamel via a sophisticated electro-chemical
technique. The Fluorinex technology delivers the
maximum amount of fluoride ions to the tooth, for
the longest period
of time known today. However, unlike other
electro-chemical based fluoride systems, no
electric current passes through the patient's
tissue, thus enhancing the safety of the device.
Fluorinex has also begun development of a tooth
whitening system based on the same principles and
technology as its fluoride delivery system.
As part of the investment agreement, Syneron will
have exclusive, worldwide distribution rights for
10 years for the tooth whitening devices and
consumables.
Syneron CEO, David Schlachet, commented,
"Fluorinex's team has proven their innovative and
technological skill with the development of their
fluoridation device. We view their success as
directly applicable to the development of a more
advanced tooth whitening device that, like the
fluoride delivery, will make aesthetic tooth
whitening treatments much more effective and
longer lasting and will enable us to serve this
growing aesthetic application.